# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

Instrument and Assay

I Background Information:

# C Proprietary and Established Names

CAPI 3 NEONAT Hb, CAPILLARYS 3 DBS Instrument

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>GKA</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 864.7415 -AbnormalHemoglobin Assay</td><td rowspan=1 colspan=1>HE - Hematology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: Clearance of a new device system   
B Measurand: Hemoglobin variants F, A, S, C, E, D and Bart’s   
C Type of Test: Qualitative, Capillary Electrophoresis

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The CAPI 3 NEONAT Hb kit is intended as a qualitative screen for the detection of normal hemoglobins (F and A) and abnormal hemoglobins (S, C, E, D and Bart’s) in blood from human new-born collected on filter paper. This analysis is performed by capillary electrophoresis with the CAPILLARYS 3 DBS instrument.

The CAPILLARYS 3 DBS instrument is a capillary electrophoresis based automated analyzer which performs a complete hemoglobin profile for the qualitative analysis of hemoglobins (A, F, S, C, D, E and Bart’s). The assay is performed on the hemolysate of whole blood samples previously collected on filter paper.

The test result must be interpreted in conjunction with other biological and clinical findings. In case of abnormal hemoglobin presence, it should be confirmed by additional tests as per local recommendations. The device is intended for professional use only.

For In Vitro Diagnostic Use only.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only D Special Instrument Requirements: CAPILLARYS 3 DBS instrument

# IV Device/System Characteristics:

# A Device Description:

The CAPI 3 NEONAT Hb kit is intended for the detection of normal hemoglobins (F and A) and abnormal hemoglobins (S, C, E, D and Bart’s) in blood from human newborns collected on filter paper. The resulting electrophoregrams are automatically evaluated for pattern abnormalities with identification of normal and pathological patterns.

The CAPI 3 NEONAT Hb kit consists of one CAPILLARYS HEMOGLOBIN(E) buffer, an alkaline buffer $\mathrm { ( p H 9 . 4 ) }$ supplied in three vials, $7 0 0 ~ \mathrm { m L }$ each per kit, Filters - five per kit, and CAPILLARYS 3 DBS MICROPLATES - one pack barcoded 96-well microplates consisting of 10 microplates.

The CAPILLARYS 3 DBS instrument has silica capillaries functioning in parallel allowing 12 simultaneous analyses. The CAPILLARYS 3 DBS performs all sequences automatically to obtain a complete hemoglobin profile for the qualitative analysis of hemoglobins. The assay is performed on the hemolysate of whole blood samples previously collected on Guthrie filter paper and punched to obtain a paper circle.

Reagents required to perform the CAPI 3 NEONAT Hb kit on CAPILLARYS 3 DBS instrument but are not supplied in the CAPI 3 NEONAT Hb kit include, CAPI 3 NEONAT Hemolysing solution kit, CAPI 3 NEONAT Hb AF control, CAPILLARYS 3 CAPICLEAN, CAPILLARYS 3 wash solution.

# B Principle of Operation:

The CAPI 3 NEONAT Hb kit is intended for the detection of normal hemoglobins (F and A) and abnormal hemoglobins (S, C, E, D and Bart’s) in dried blood samples from newborns collected on filter paper. The samples are eluted from the filter paper into microplates.

The CAPILLARYS 3 DBS instrument performs fully automated electrophoresis sequencing on the hemolysate of whole blood samples previously collected on Guthrie filter paper and punched to obtain a paper circle collected in microplates. The CAPI 3 NEONAT Hb kit in conjunction with CAPILLARYS 3 DBS instrument utilizes the principle of capillary electrophoresis in free solution. With this technique, charged molecules are separated by their electrophoretic mobility in an alkaline buffer with a specific $\mathsf { p H }$ . Separation also occurs according to the electrolyte pH and electroosmotic flow. The hemoglobins, separated in silica capillaries, are directly detected at an absorbance wavelength of $4 1 5 \mathrm { n m }$ . The hemoglobin (Hb) fractions are separated by absorbance spectrophotometry.

# C Instrument Description Information:

1. Instrument Name: CAPILLARYS 3 DBS instrument

2. Specimen Identification: Single use microplates with barcodes

3. Specimen Sampling and Handling: Whole blood samples collected from newborns on Guthrie cards (Whatman cards) and dried for a minimum of 4 hours at room temperature $( 1 5 \mathrm { - } 3 0 ^ { \circ } \mathrm { C } )$ .

4. Quality Control: CAPI 3 NEONAT Hb AF CONTROL, Hb AFSC CONTROL

# V Substantial Equivalence Information:

A Predicate Device Name(s): Capillarys Neonat Hb

# C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K232027</td><td colspan="1" rowspan="1">K091283</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">CAPI 3 NEONAT HbCAPILLARYS 3 DBSInstrument</td><td colspan="1" rowspan="1">CAPILLARYS NEONAT Hbwith CAPILLARYS 2System</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">The CAPI 3 NEONATHb kit is intended as aqualitative screen for thedetection of normalhemoglobins (F and A)and abnormalhemoglobins (S, C, E, Dand Bart's) in bloodfrom human new-borncollected on filter paper.This analysis isperformed by capillaryelectrophoresis with theCAPILLARYS 3 DBSinstrument.The CAPILLARYS 3DBS instrument is acapillary electrophoresisbased automatedanalyzer which performsa complete hemoglobinprofile for thequalitative analysis ofhemoglobins (A, F, S,C, D, E and Bart's). Theassay is performed onthe hemolysate of wholeblood samplespreviously collected onfilter paper.</td><td colspan="1" rowspan="1">The CAPILLARYSNEONAT Hb kit is designedfor the separation of thenormal hemoglobins (F andA) in blood samples fromhuman new-borns, and forthe detection of the majorhemoglobin variants (S, C, E,D and Bart's), byelectrophoresis in alkalinebuffer (pH 9.4) with theCAPILLARYS 2 system. TheCAPILLARYS NEONAT Hbkit is designed for laboratoryuse. The CAPILLARYS 2 isan automated analyzer whichperforms a completehemoglobin profile for thequalitative analysis ofhemoglobins. The assay isperformed on the hemolysateof whole blood samplespreviously collected on filterpaper.For In Vitro Diagnostic Useonly.</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">The test result must beinterpreted inconjunction with otherbiological and clinicalfindings. In case ofabnormal hemoglobinpresence, it should beconfirmed by additionaltests as per localrecommendations. Thedevice is intended forprofessional use only.</td><td colspan="1" rowspan="1">−</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Hemoglobin variants (F,A, S, C, E, D and Bart's)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measurement</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Matrix</td><td colspan="1" rowspan="1">Blood samples fromhuman newbornscollected on filter paper</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Capillaryelectrophoresis</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrument WavelengthMeasurement</td><td colspan="1" rowspan="1">415 nm</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Buffer</td><td colspan="1" rowspan="1">CAPILLARYSHEMOGLOBIN(E)buffer</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Hb AF ControlHb AFSC Control</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicDifferences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Kit components</td><td colspan="1" rowspan="1">•  CAPILLARYSHEMOGLOBIN(E)buffer•  FiltersCAPILLARYS 3DBSMICROPLATES</td><td colspan="1" rowspan="1">•  CAPILLARYSHEMOGLOBIN(E)buffer• FiltersDilution segmentsHemolyzing Solution• Washing Solution</td></tr><tr><td colspan="1" rowspan="1">Dilution Vessel</td><td colspan="1" rowspan="1">96 well-microplates</td><td colspan="1" rowspan="1">Dilution segments</td></tr><tr><td colspan="1" rowspan="1">Punch Size</td><td colspan="1" rowspan="1">3.2 mm diameter</td><td colspan="1" rowspan="1">3.8 mm diameter</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">CAPILLARYS 3 DBSInstrument</td><td colspan="1" rowspan="1">CAPILLARYS 2 SYSTEM</td></tr></table>

# VI Standards/Guidance Documents Referenced:

• CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures, 3rd Edition   
• CLSI EP07-A3: Interference Testing in Clinical Chemistry; Approved Guideline. 3rd Edition   
• CLSI EP12-A2: User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline. 2nd Edition   
• CLSI EP25: Evaluation of Stability of In Vitro Medical Laboratory Test Reagents, 2nd Edition   
• CLSI NBS01: Dried Blood Spot Specimen Collection for Newborn Screening, 7th Edition   
• IEC 61010-1 Edition 3.1 2017-01, Safety requirements for electrical equipment for measurement, control, & laboratory use - Part 1   
• IEC 60601-1-2 Edition 4.1 2020-09, Medical electrical equipment - Part 1-2: General requirements   
• IEC 62304 Edition 1.1 2015-06, Medical device software - Software life-cycle processes   
• IEC 62366-1:2015+A1:2020, Medical devices Part 1: Application of usability engineering to medical devices

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

# 1. Precision/Reproducibility:

Precision of the CAPI 3 NEONAT Hb on the CAPILLARYS 3 DBS instrument was evaluated according to CLSI guideline EP05-A3.

20-day precision study using hemoglobin control

Two control materials (AF and AFSC) with different hemoglobin variants were run using one lot of the CAPI 3 NEONAT Hb kit performed with one CAPILLARYS 3 DBS instrument. Each sample was analyzed in one replicate on 12 capillaries per run, two runs per day over 20 days yielding a total of 480 results per sample. Within-run, between-day, between-run, and total precision were determined. All precision estimates for all Hb fractions were within the acceptance criteria.

%Hb F   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AF</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>69.2</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>26.0</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>0.60</td></tr></table>

%Hb A   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AF</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>30.2</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>1.70</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>2.30</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>46.6</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>0.80</td></tr></table>

%Hb S   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>16.6</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>1.00</td></tr></table>

%Hb C   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>10.7</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>1.00</td></tr></table>

Reagent lot-to-lot precision study using hemoglobin control

Two control materials with different hemoglobin variants were run using three lots of the CAPI 3 NEONAT Hb kit performed with one CAPILLARYS 3 DBS instrument. Each sample was analyzed in three replicates per run, two runs per day over five days for each of the three reagent lots yielding a total of 90 results per sample. Within-run, between run, between-day, between-lot and total precision were calculated. All hemoglobin fractions met acceptance criteria demonstrating acceptable reagent lot-to-lot precision.

%Hb F   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AF</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>69.3</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>25.8</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>0.60</td></tr></table>

%Hb A   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AF</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>30.3</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>1.40</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>47.1</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>1.00</td></tr></table>

%Hb S   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>16.5</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>1.60</td></tr></table>

%Hb C   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>1.80</td></tr></table>

Between-Instrument Precision using hemoglobin control Two control materials with different hemoglobin variants were run using one lot of the CAPI 3 NEONAT Hb kit performed with three CAPILLARYS 3 DBS instruments. Each sample was analyzed in three replicates per run, two runs per day over five days yielding a total of 90 results per sample. The results are expressed as standard deviation (SD) and coefficient of variation $( \% C V )$ . Within-run, between-run, between-day, between-instrument, and total precision were calculated. All hemoglobin fractions met acceptance criteria demonstrating acceptable between-instrument precision.

%Hb F   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AF</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>69.4</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>25.9</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>0.60</td></tr></table>

%Hb A   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AF</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>29.9</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>0.73</td><td rowspan=1 colspan=1>2.40</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>46.6</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>1.20</td></tr></table>

%Hb S   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>16.7</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>1.70</td></tr></table>

%Hb C   

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>1.80</td></tr></table>

# Precision study using patient samples

Within-run precision was determined at an internal site by running six newborn whole blood native samples (FA, FAS, FAC, FAD, FAE and FA Bart's patterns) and control samples (FA and AFSC). Each sample was analyzed using one lot of CAPI 3 NEONAT Hb kit in single run on 12 capillaries on one CAPILLARYS 3 DBS instrument. All electropherograms were evaluated visually. All replicates gave concordant results and the patterns corresponded to the hemoglobin type of each tested sample.

Lot-to-lot precision study was performed by running six newborn whole blood native samples (FA, FAS, FAC, FAD, FAE and FA Bart's patterns) and two control samples (FA and AFSC). Each sample was analyzed once per run over two runs with three lots of CAPI 3 NEONAT Hb kit on one CAPILLARYS 3 DBS instrument for three days. One lot of CAPI 3 NEONAT Hb kit was tested on each of the three days. All electropherograms were evaluated visually. All replicates gave concordant results and the patterns corresponded to the hemoglobin type of each tested sample.

Between-instrument precision study was performed by running six newborn whole blood native samples (FA, FAS, FAC, FAD, FAE and FA Bart's patterns) and two control samples (FA and AFSC). Each sample was analyzed once per run over two runs with one lot of CAPI 3 NEONAT Hb kit on three CAPILLARYS 3 DBS instruments. The study was performed for three days with testing performed on one instrument each day. All electropherograms were evaluated visually. All replicates gave concordant results and the patterns corresponded to the hemoglobin type of each tested.

Precision with patient samples   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Identificationpattern</td><td rowspan=1 colspan=2>Between capillaries</td><td rowspan=1 colspan=2>Between-lot</td><td rowspan=1 colspan=2>Between-instrument</td><td rowspan=1 colspan=2>Between-day</td></tr><tr><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Totalanalyses</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Totalanalyses</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Totalanalyses</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Totalanalyses</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>FA</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>FAS</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>FAC</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>FAD</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>FAE</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>FA Bart&#x27;s</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>AFSC</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>FA</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>100%concordance</td><td rowspan=1 colspan=1>120</td></tr><tr><td rowspan=1 colspan=2>Total concordance(95% CI)</td><td rowspan=1 colspan=1>100%(96.2%,100.0%)</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>100%(96.7%,100.0%)</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>100%(96.7%,100.0%)</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>100%(98.0%,100.0%</td><td rowspan=1 colspan=1>190</td></tr></table>

2. Linearity:

Not applicable

# 3. Analytical Specificity/Interference:

The interference studies were conducted in accordance with CLSI EP07-A3 using six neonate whole blood samples collected on Guthrie cards. The samples consisted of FA, FAS, FAC, FAD, FAE, FA Bart's and were analyzed at one internal site. Paired interference testing was performed where test samples were supplemented with the potential interferent, and results were compared to reference samples supplemented with same volume of solvent as the interferent solution. The testing was performed using two lots of CAPI 3 NEONAT kit on two CAPILLARYS 3 DBS instruments with samples run in one replicate. The results were evaluated visually for hemoglobin patterns.

No interference with the CAPI 3 NEONAT Hb kit used on the CAPILLARYS 3 DBS instrument was detected due to the newborn whole blood sample’s high concentration of the following interfering factors listed below:

<table><tr><td rowspan=1 colspan=1>Interference</td><td rowspan=1 colspan=1>Maximum concentration tested withno interference</td></tr><tr><td rowspan=1 colspan=1>Conjugated bilirubin</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Unconjugated bilirubin</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>1500 mg/dL</td></tr></table>

4. Assay Reportable Range: Not Applicable

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

a. Shelf-life Stability

The sponsor stated that the CAPILLARYS HEMOGLOBIN (E) buffer in the CAPI 3 NEONAT Hb kit is unchanged as in the CAPILLARYS NEONAT Hb kit reviewed in K091283. The established shelf-life for the CAPILLARYS HEMOGLOBIN (E) buffer is up to three years when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

# b. On-board stability of CAPI 3 NEONAT Hb

On-board reagent stability of the CAPILLARYS HEMOGLOBIN(E) buffer was conducted using one lot of CAPILLARYS HEMOGLOBIN(E) buffer boarded on one CAPILLARYS 3 DBS instrument as per CLSI EP25 Ed2. Six samples: two each of FA and FAS, one of Hb AFSC control and one of Hb AF CAPI 3 NEONAT control were used in the study. Testing was performed on day 1, 15, 31 and 38 days of CAPILLARYS HEMOGLOBIN(E) buffer on board the CAPILLARYS 3 DBS instrument. The results were evaluated visually for hemoglobin patterns and stability was demonstrated if the identification pattern was identical between the reference and time points tested for all replicates. The study supports on-board stability of one month of the CAPILLARYS HEMOGLOBIN(E) buffer once on board the CAPILLARYS 3 DBS instrument.

# c. Sample stability

The sample stability study was conducted to evaluate the stability of native neonate whole blood samples collected and stored on Guthrie cards. The whole blood samples were comprised of both normal and pathological hemoglobin variants (FA, FAS, FAC, FAE, FCE, FSC, FAX and FA Bart’s) collected on Guthrie cards and stored at room temperature $( 1 5 \mathrm { - } 3 0 ^ { \circ } \mathrm { C } )$ for 16 days, followed by storage at $2 { - } 8 ^ { \circ } \mathrm { C }$ for 2 months $+ 1$ day (from day 0 of whole blood collection). The testing was performed using one lot of CAPI 3 NEONAT Hb kit on one CAPILLARYS 3 DBS instrument. The samples were tested at each timepoint in one replicate. The results were evaluated visually for hemoglobin patterns and stability was demonstrated if the identification pattern was identical between the reference and time points tested. The study supports whole blood samples dried on Guthrie cards may be stored for 15 days at room temperature and no longer than 2 months at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

d. Sample transportation study

The sample transportation study was conducted to evaluate the transportation stability of native neonate whole blood samples collected on Guthrie cards. Two separate studies mimicking different environmental conditions were conducted. Twelve (12) neonate whole blood samples, both normal and pathological (six samples with FA, five samples with FAS ad one sample with FAC) collected on Guthrie cards were used for the study. In the first study, the samples were tested at the beginning of the study $( \mathrm { T } { = } 0 )$ and after storage period of 8 days at $3 0 \mathrm { { } ^ { \circ } C }$ with exposure of a high hygrometry $> 9 5 ~ \%$ . The results were evaluated visually for hemoglobin patterns and stability was demonstrated if the identification pattern was identical between the reference and time points tested. In the second study, samples after initial analysis $( \mathrm { T } { = } 0 )$ , were stored in a sealed opaque plastic bag, in an envelope for 5 days where samples were cycled between $3 7 ^ { \circ } \mathrm { C }$ for 6 hours followed by storage at $2 { - } 8 ^ { \circ } \mathrm { C }$ each day. After sample analysis on day 6, samples were stored at $3 0 ^ { \circ } \mathrm { C }$ for another period of 11 days. At the end of 16 days (5 days cycled at different temperatures and 11 days at $3 0 ^ { \circ } \mathrm { C }$ ) sample analysis was performed. The results were evaluated visually for hemoglobin patterns at $\mathrm { T } { = } 0$ , 6 and 16 days, and stability was demonstrated if the identification pattern was identical between the reference and time points tested. The results met the acceptance criteria and samples were found to be stable during transport.

6. Detection Limit: Not applicable

7. Assay Cut-Off: Not applicable

8. Accuracy (Instrument): Not applicable

9. Carry-Over:

The carryover study was conducted to evaluate sample retention in the capillary. Two neonate whole blood samples, one normal (FA) and one pathological (FS) collected on Guthrie paper were used in the study. Carry-over was assessed by the normal hemoglobin run followed by the pathological hemoglobin run. For all normal samples analyzed after pathological samples, the identification pattern was found unchanged. No carry-over is observed with the CAPI 3 NEONAT Hb kit used on the CAPILLARYS 3 DBS instrument.

# B Comparison Studies:

# 1. Method Comparison with Predicate Device:

The study was conducted at three sites, one internal and two external sites. The results from CAPI 3 NEONAT Hb kit performed on the CAPILLARYS 3 DBS instrument were compared to the predicate CAPILLARYS NEONAT Hb kit on CAPILLARYS 2 instrument using the CAPILLARYS NEONAT Fast procedure (K091283). A total of 789 newborn

whole blood samples collected on Guthrie cards consisting of 401 normal samples (FA) and 388 pathological samples (FAS, FAC, FAD, $\mathrm { F A + }$ Bart’s, $\mathrm { F A S + }$ Bart’s, FAE, FS, FSA, FAX, FCS, AFS, FSE, FCX, FE and $\mathrm { F A C + }$ Bart’s) were included in the study. One lot of CAPI 3 NEONAT Hb kit and one CAPILLARYS 3 DBS instrument were used at each site. The overall percent agreement (OPA), positive percent agreement (PPA), the negative percent agreement (NPA), and their $9 5 \%$ confidence intervals $9 5 \%$ CI by Wilson score method) were calculated for the CAPI 3 NEONAT Hb kit compared to the predicate device. The method comparison study showed an OPA of $100 \%$ ( $9 5 \% C \mathrm { I }$ : $9 6 . 5 \%$ , $100 \%$ ), a PPA of $100 \%$ $9 5 \% \mathrm { C I }$ : $9 6 . 5 \%$ , $1 0 0 \%$ ) and an NPA of $100 \%$ ( $9 5 \% C \mathrm { I }$ : $9 6 . 6 \%$ , $100 \%$ ) between the candidate and the predicate devices.

2. Matrix Comparison: Not applicable

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable

2. Clinical Specificity: Not applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable

# D Clinical Cut-Off:

Not applicable

# E Expected Values/Reference Range:

Not applicable

# F Other Supportive Instrument Performance Characteristics Data:

Sample preparation study

The sample preparation study was conducted to evaluate the performance of samples eluted using passive (2 hours or up to 3 days at $2 { - } 8 ^ { \circ } \mathrm { C }$ ) and active elution (40 minutes at room temperature) methods and tested using CAPI 3 NEONAT Hb kit on CAPILLARYS 3 DBS instrument. Twelve (12) neonate whole blood samples collected on Guthrie paper comprised of both normal and pathological samples were used in the study (3 FA, 3 FAS, 1 FAC, 1 FAD, 3 FAE and 1 Bart's). Identical electrophoretic patterns were noted between the active and passive elution sample preparation methods.

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.